Michael Thomsen Blog
Fasting for Weight Loss
Low Carb versus Balanced Carbs: Same effect.
No value of adding protein supplement during very-low-calorie diets
Enter your text here ...
Intermittent fasting with the 5:2 diet: 7 kg over six months
Weight-loss diets not only reduce body weight they can also significantly improve blood pressure control in hypertensive patients. This study compared the effects of intermittent energy restriction (5:2 diet) with those of continuous energy restriction on blood pressure control and weight loss in 205 overweight and obese patients with hypertension during a 6-month period. The continuous energy restriction was based on consuming 1,000 kcal/day for women and 1,200 kcal/day for men – which may have been about half their normal intake. The diets were equally effective for weight loss and blood pressure control. The weight loss was around 7 kg or a little over 1 kg per month of the six-month trial. The diet reduced the systolic blood pressure by 7 mm Hg and 5-6 mm Hg. There were also favourable improvements in body composition, HbA1c, and blood lipid levels, with no differences between groups (He et al. 2021). This weight loss does not seem great considering the effort required to stick to such a low-calorie diet for such a long time.
In another year-long study the 5:2 diet with or without support group sessions was compared with a one-off standard weight-management advice in 300 adults with breast cancer.The 5:2 diet did not seem particularly effective for weight loss in this group. This may have been related to adherence which declined to just 22% at the end of the study. Adherence to the 5:2 diet was initially high (74% at 6 weeks), but it declined over time (31% at 6 months and 22% at one year). The weight loss was only around two kilograms (Harvie et al. 2021).
A mega review of 130 randomised trials finds significant differences in various types of intermittent fasting diets
An umbrella review of 11 meta-analyses of 130 randomized clinical trials found six statistically significant associations of intermittent fasting supported by moderate to high quality of evidence. Outcomes associated with modified alternate-day fasting included a moderate reduction of body weight, body mass index, and cardiometabolic risk factors in adults with overweight or obesity. Only one association was supported by high-quality evidence: modified alternate-day fasting for 1 to 2 months, which was associated with moderate reduction in body mass index in healthy adults and adults with overweight, obesity, or non-alcoholic fatty liver disease compared with regular diet.
It is important to note that the modified alternate day fasting (MAFD) and the 5:2 diet were the only intermittent fasting types that were associated with statistically significant weight loss of more than 5% in adults with overweight or obesity. In contrast, zero-calorie alternate day fasting, and time restricted eating did not. The MADF is a very different diet to the 5:2 diet and incorporated repeated days of significant calorie restriction. It alternated between days of ad libitum eating and days of fasting with total caloric intake ranging from 0% to 40% or 0 to 600 kcal per day for 3 to 5 days per week. It is also worth noting that the IF diets were more successful in the initial phase (ie, 1-6 months), after which participants would frequently experience a plateau as additional weight loss was not further achieved because of the metabolic adaptation of the human body or decreased adherence to the assigned weight loss strategy. Lastly, many trials had a high degree of bias with partly because of the lack of masking participants and personnel (Patikorn et al. 2021).
Weigh loss during the Fasting Mimicking Diet (FMD)
Participants in the first clinical trial on the FMD, who were generally healthy and not very overweight, lost 2.5 kg after three cycles of fasting mimicking diet (Wei et al. 2017). Importantly, the weight loss is loss of body fat, especially around the waist, with a reduction in waist circumference of 4 cm. The 5-day FMD has been shown to preserve muscle mass during the programme. Much greater weight loss has been observed in clinical practice in overweight patients with repeated cycles of the FMD.
Harvie, M., M. Pegington, S. J. Howell, N. Bundred, P. Foden, J. Adams, L. Graves, A. Greystoke, M. P. Mattson, R. G. Cutler, J. Williamson, K. Livingstone, D. McMullen, K. Sellers, C. Lombardelli, G. Cooper, S. McDiarmid, and A. Howell. 2021. 'Randomised controlled trial of intermittent vs continuous energy restriction during chemotherapy for early breast cancer', Br J Cancer.
He, C. J., Y. P. Fei, C. Y. Zhu, M. Yao, G. Qian, H. L. Hu, and C. L. Zhai. 2021. 'Effects of Intermittent Compared With Continuous Energy Restriction on Blood Pressure Control in Overweight and Obese Patients With Hypertension', Front Cardiovasc Med, 8: 750714.
Magkos, F., M. F. Hjorth, S. Asping, M. I. Rosenkrans, S. I. Rasmussen, C. Ritz, A. Sjodin, and N. R. W. Geiker. 2021. 'A protein-supplemented very-low-calorie diet does not mitigate reductions in lean mass and resting metabolic rate in subjects with overweight or obesity: A randomized controlled trial', Clin Nutr, 40: 5726-33.
Naude, C. E., A. Brand, A. Schoonees, K. A. Nguyen, M. Chaplin, and J. Volmink. 2022. 'Low-carbohydrate versus balanced-carbohydrate diets for reducing weight and cardiovascular risk', Cochrane Database Syst Rev, 1: CD013334.
Patikorn, Chanthawat, Kiera Roubal, Sajesh K. Veettil, Viji Chandran, Tuan Pham, Yeong Yeh Lee, Edward L. Giovannucci, Krista A. Varady, and Nathorn Chaiyakunapruk. 2021. 'Intermittent Fasting and Obesity-Related Health Outcomes: An Umbrella Review of Meta-analyses of Randomized Clinical Trials', JAMA Network Open, 4: e2139558-e58.
Wei, M., S. Brandhorst, M. Shelehchi, H. Mirzaei, C. W. Cheng, J. Budniak, S. Groshen, W. J. Mack, E. Guen, S. Di Biase, P. Cohen, T. E. Morgan, T. Dorff, K. Hong, A. Michalsen, A. Laviano, and V. D. Longo. 2017. 'Fasting-mimicking diet and markers/risk factors for aging, diabetes, cancer, and cardiovascular disease', Sci Transl Med, 9.
When you subscribe to the blog, we will send you an e-mail when there are new updates on the site so you wouldn't miss them.
Book Review: Phytotherapy Desk Reference
Reviewed by Mim Beim
My original copy of Michael Thomsen’s Phytotherapy Desk Reference is herb-stained and dog-eared. So it was with much excitement that I received the latest edition of this little gem.
The book, as with the previous editions, has been designed not as an exhaustive materia medica but rather as a desk reference for the busy herbalist. It contains short, precise descriptions of 236 of the most commonly used herbs in Australia and New Zealand.
The extensively revised and updated 5th edition of the Phytotherapy Desk Reference
Phytotherapy Desk Reference 5th Edition ISBN: 978-0-646-82443-7 Soft-cover, spiral bound. 200 pages. 233 Monographs.